KYMAB

Serial Number 88441516
Registration 6473731
700

Registration Progress

Application Filed
May 22, 2019
Under Examination
Approved for Publication
Mar 23, 2021
Published for Opposition
Mar 23, 2021
Registered
Sep 7, 2021

Trademark Image

KYMAB

Basic Information

Serial Number
88441516
Registration Number
6473731
Filing Date
May 22, 2019
Registration Date
September 7, 2021
Published for Opposition
March 23, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 7, 2021
Registration
Registered
Classes
005 042 044

Rights Holder

Kymab Limited

99
Address
The Bennet Building (B930)
Babraham Research Campus
Cambridge CB223AT
GB

Ownership History

Kymab Limited

Original Applicant
99
Cambridge GB

Kymab Limited

Owner at Publication
99
Cambridge GB

Kymab Limited

Original Registrant
99
Cambridge GB

Legal Representation

Attorney
Mark H. Tidman

USPTO Deadlines

Next Deadline
682 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-09-07)
Due Date
September 07, 2027
Grace Period Ends
March 07, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description Documents
Sep 7, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 1, 2021 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Loading...
Apr 21, 2021 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Mar 23, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 23, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 3, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 17, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Feb 17, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Feb 17, 2021 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Feb 17, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 17, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Oct 9, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Oct 9, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Oct 9, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 22, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 21, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 21, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 16, 2020 GNRT O NON-FINAL ACTION E-MAILED Loading...
Mar 16, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 16, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 9, 2020 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Feb 21, 2020 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Feb 21, 2020 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Feb 14, 2020 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Feb 14, 2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Feb 14, 2020 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Feb 14, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 14, 2020 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 29, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 28, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 28, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 9, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 9, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 9, 2019 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 9, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 6, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 25, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, autoimmune and infectious diseases, and medical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodies, for medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases and in the field of antibodies and immuno-oncology
Class 042
Scientific, medical and technological services, namely, scientific research, analysis and testing in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology, and scientific research, analysis and testing in the field of antibodies and cell repertoires and research, development and design in the field of science, medicine, and technology; industrial analysis and industrial research services, namely, testing, analysis, and evaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, haematology and infectious disease; Conducting clinical trials for others in the field of antibodies, and medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discovery, clinical development, antibodies and biological cells; chemical analysis; chemical research
Class 044
Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics; Medical screening

Classification

International Classes
005 042 044